Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
276. |
ECCT/19/11/06 | Optimize LNG EC An Open Label Phase 2 Pharmarcokinetic Study to Evaluate Double - Dose Levonorgestrel Emergency Contraception in Combination withEfavirenz Based Antiretroviral Therapy or Rifampicin Containing Anti - Tuberculosis Therapy. A5375 |
Principal Investigator(s) 1. Lucy Chepkurui Koech Site(s) in Kenya KEMRI/WRP Kericho |
View |
277. |
ECCT/20/04/02 | PROSYNK Study A 4-arm, open-label, individually randomized, controlled, phase-2, study of a probiotic and two synbiotics in young children in western Kenya. |
Principal Investigator(s) 1. Stephen Allen Site(s) in Kenya 1. Homa Bay County Referral Hospital (Homa Bay county) 2. Siaya County Referral Hospital (Siaya county) 3. Migori County Referral Hospital (Migori county) 4. Rongo Sub-County Hospital (Migori county) 5. Rachuonyo Sub County Hospital (Homa Bay county) 6. Kendu Bay Sub-County Hospital (Homa Bay county) 7. Ahero County Hospital (Kisumu county) 8. Rabuor Sub-County Hospital (Kisumu county) 9. Akala Sub-County Hospital (Siaya county) 10. Bondo Sub-County Hospital (Siaya county) |
View |
278. |
ECCT/19/11/05 | Point-of-care Urine Monitoring of Adherence (PUMA) Point-of-care Urine Monitoring of Adherence (PUMA): Testing a Real-Time Urine Assay of Tenofovir in PrEP Pilot trial to examine the feasibility, acceptability and impact on longer-term adherence of an intervention using a new urine-based tenofovir adherence assay |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR PHRD (THIKA) PROJECT |
View |
279. |
ECCT/19/11/03 | A Pilot BE study for Enalpril 5mg A bioequivalent pilot study of a locally-produced brand of enalapril tablets: a key step towards implementation of bioequivalent study regulatory requirements in East Africa |
Principal Investigator(s) 1. Simon Njoroge Njenga Site(s) in Kenya Kenya Medical Research Institute |
View |
280. |
ECCT/19/11/04 | Second line switch to Dolutegravir (2SD) study Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults from Ritonavir boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial |
Principal Investigator(s) 1. Loice Achieng Site(s) in Kenya 1. Kenyatta National Hospital (Nairobi City county) 2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 3. Thika Level 5 Hospital (Kiambu county) 4. Kiambu Level 5 Hospital (Kiambu county) |
View |